|
|
|
(from left)
|
Mr. Kailian is a General Partner of MPM Capital LP, a leading healthcare venture capital firm. He was Vice Chairperson of the Board of Directors of Millennium Pharmaceuticals, Inc. from February 2002 until December 2004. He served as CEO, President and Director of COR Therapeutics, Inc., a biotechnology company, from 1990 until its acquisition by Millennium in 2002. Prior to this, Mr. Kailian was employed by Marion Merrell Dow, Inc., a pharmaceutical company, and its predecessor companies, in various international and U.S. management, marketing and sales positions from 1967 to 1990, including President and General Manager, Merrell Dow USA and Corporate Vice President of Global Commercial Development, Marion Merrell Dow, Inc. Mr. Kailian currently is the Chairman of the Board of ViaCell, Inc., a biotechnology company, and a director of NicOx, S.A., a pharmaceutical company. He is also a director of BIO Ventures for Global Health.
In 2001, Mr. Moley was nominated by President George W. Bush to serve as Ambassador and U.S. Permanent Representative to the United Nations and Other International Organizations in Geneva, and served in that position from September 2001 to April 2006. Mr. Moley also served in the administration of George H.W. Bush as an Assistant Secretary of the U.S. Department of Health and Human Services (HHS) from 1989 to 1992, and as the Deputy Secretary of HHS from 1992 to 1993. In addition to his government service, Mr. Moley was President and Chief Executive Officer of Integrated Medical Systems Inc. from 1996 to 1998 and was a Senior Vice President of PCS Health Systems, Inc. from 1993 to 1996. Mr. Moley also has served on the Board of Directors of several other companies. Ambassador Moley previously served as a member of the Cephalon Board of Directors from 1994 to 2001.
Since July 2004, Mr. Greenacre has served as Chairman of Beijing Med-Pharm Corporation, a pharmaceutical company. Mr. Greenacre also has served since 2002 as Chairman of Life Mist Technologies, Inc., a fire suppression equipment company. From 1997 to 2001, Mr. Greenacre served as Chief Executive Officer and director of Delsys Pharmaceutical Corporation, a formulation and drug delivery system company. From 1993 to 1997, Mr. Greenacre served as President and Chief Executive Officer and as a director of Zynaxis Inc., a biopharmaceutical company. From 1989 to 1992, Mr. Greenacre was Chairman Europe, SmithKline Beecham Pharmaceutical company. He joined SmithKline & French in 1973, where he held positions of increasing responsibility in its European organization. Mr. Greenacre currently serves as a director of Acusphere, Inc., a drug delivery company, Curis, Inc., a biotechnology company, and Immune Response Corp., a vaccine company.
Dr. Baldino founded Cephalon in 1987 and grew it from a privately held company to the sixth largest publicly traded biotechnology company in the U.S., with 2005 revenue exceeding $1.2 billion. Cephalon expects to propel its annual revenue to $2 billion by 2008 with dramatic growth of its core products combined with new product launches, acquisitions and industry collaborations.
Dr. Baldino has nearly two decades of scientific experience in neurobiology, molecular biology and electrophysiology, and has authored more than 100 publications in peer-reviewed journals such as Nature, Journal of Neuroscience Research and Brain Research. Dr. Baldino received his Ph.D. in pharmacology from Temple University. From 1981-1987, Dr. Baldino served as senior research biologist in the medical products department at E.I. duPont de Nemours & Company, where he was responsible for developing research strategies for identifying novel neuropharmaceutical agents.
Dr. Baldino Chairs the Executive Council of the Harvard Division of Sleep Medicine, and is a member of the Board of Trustees at Temple University and The Franklin Institute. In addition, Dr. Baldino serves as a member of the Board of Directors for the Greater Philadelphia Chamber of Commerce, the Eastern Technology Council, NicOx, S.A., PhRMA, BioAdvance Biotechnology Greenhouse Corp., Biotechnology Industry Association (BIO), Pharmacopeia Drug Discovery, Inc., Quaker BioVentures, L.P., Pennsylvania Biotechnology Association, and Acusphere, Inc. He is also a member of the Healthcap Advisors Board and the Vantage Point Venture Partners Advisory Committee. Dr. Baldino also holds several adjunct academic appointments, and serves on the Muhlenberg College Board of Observers.
Dr. Sanders is retired from Glaxo, Inc., where he served as Chief Executive Officer from 1989 through 1994 and Chairman of the Board from 1992 through 1995. He also has served on the Board of Directors of Glaxo plc. Previously, Dr. Sanders held a number of positions at Squibb Corporation. Dr. Sanders currently serves as a director of BioPure Corporation, an oxygen therapeutics company; Fisher Scientific International, a provider of equipment, supplies, and services for the clinical laboratory and global scientific research markets; Genentech, Inc., a biopharmaceutical company; Icagen, Inc., a biopharmaceutical company; and Vertex Pharmaceuticals, a biotechnology company.
Mr. Winger is designated as the Audit Committee Financial Expert. He currently serves as Senior Vice President and Chief Financial Officer of Applera Corp., a life sciences company, where he is responsible for developing financial and business strategies. He is a member of Applera’s Executive Committee. From 1989 to 1997, Mr. Winger served as Senior Vice President, Finance and Administration, and Chief Financial Officer of Chiron Corporation. From 1982 to 1989, Mr. Winger was with Cooper Companies, Inc., where he held positions of increasing responsibility, including that of Chief Financial Officer. Prior to this, Mr. Winger was with Continental Can Company holding a number of positions including Head of Finance for its international division and General Manager of its Latin American Operations. Mr. Winger currently serves as a director of A.P. Pharma, a specialty pharmaceutical company, and Cell Genesys, Inc., a pharmaceutical company.
Mr. Egan is a founder and general partner of Alta Communications, a venture capital firm. He founded Alta’s predecessor firm, Burr, Egan, Deleage & Co. in 1979 and has identified and backed several of America’s leading growth companies in the communications and information industries.
Dr. Wilensky serves as a Senior Fellow at Project HOPE, an international health education foundation, which she joined in 1993. From 1997 to 2001, Dr. Wilensky chaired the Medicare Payment Advisory Committee, which advises Congress on all issues relating to Medicare. In November 2004, Dr. Wilensky was appointed as the Vice Chair of the Maryland Health Care Commission. Dr. Wilensky also is an elected member of the Institute of Medicine and its Governing Council, and serves as a trustee of the Combined Benefits Fund of the United Mineworkers of America and the National Opinion Research Center of the University of Chicago. Dr. Wilensky currently serves as a director of Gentiva Health Services, a specialty pharmaceutical and home health care company, ManorCare, a provider of health care services, Quest Diagnostics, Inc., a leading provider of diagnostic testing, information and services, SRA International, Inc., a provider of information technology services to the government, and UnitedHealth Group, a health care company.
Back to top
|
|